Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multicenter trial of treatment for young ALL patients. All ALL patients will receive the same steroid pre-phase in order to evaluate sensitivity or resistance. Then, patients will be included into 3 specific trials according to biological features (immunophenotype, cytogenetics, and molecular biology).

Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2005:

• T ALL or B ALL non Ph (N=810 patients planned).

• GRAALL 2005 R: B ALL non Ph CD20+ (N=220 patients planned).

• GRAAPH 2005: ALL Ph+ (N=270 patients planned)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Group for Research in Adult Acute Lymphoblastic Leukemia
• Treatments: Imatinib Mesylate; Rituximab

Criteria

Inclusion Criteria:

• 18-59 years

• ALL newly diagnosed (blast < 20%)

• Central Nervous System (CNS) positive or negative

• Signed written informed consent

• For GRAAPH trial only: t(9;22) or BCR- ABL positive

Exclusion Criteria:

• Lymphoblastic lymphoma

• ALL 3

• Chronic myeloid leukemia

• Severe organ condition